Accordingly, we found that high expression of PPM1D in wild-type p53 tumors correlates with poor prognosis, which is in a good agreement with previously published data.45, 46 This justifies the development of Wip1 inhibitors to enhance p53-positive tumors treatments, such as neuroblastoma.11 In contrast, in p53-negative tumors, high expression of PPM1D correlates with better prognosis. The gene discussed is PPM1D; the disease is neuroblastoma.